Physician profile
Erika E Degayner
NPI 1184740169
$16,535.29
in general payments reported to CMS, 2019-2025
29 companies · $1,699 in 2025
The $1,699 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $580 · 2021: $874 · 2022: $1,294 · 2023: $1,312 · 2024: $10K · 2025: $1,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,150 · Food and Beverage: $4,944 · Travel and Lodging: $883 · Education: $53.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,150.00 |
| Food and Beverage | $4,944.41 |
| Travel and Lodging | $883.03 |
| Education | $53.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $7,457.63 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $2,345.86 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Abbvie INC. | $2,070.13 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $777.34 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $754.31 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $564.17 | 2019-2025 | Epclusa |
| Celgene Corporation | $451.64 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $429.24 | 2019-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $295.43 | 2020-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $244.51 | 2022-2025 | Dupixent |
| Pfizer INC. | $169.65 | 2019-2025 | |
| Medtronic, INC. | $146.90 | 2024-2025 | Interstim |
| E.R. Squibb & Sons, L.L.C. | $121.14 | 2022-2023 | |
| Genzyme Corporation | $103.02 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $99.10 | 2024-2025 | Iqirvo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $86.72 | 2022-2025 | Suflave, Sutab |
| Ucb, INC. | $67.67 | 2019-2020 | |
| Ardelyx, INC. | $53.65 | 2025 | Ibsrela |
| Shionogi INC | $50.07 | 2019-2020 | |
| Celltrion USA INC. | $40.43 | 2025 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $37.66 | 2021-2022 | |
| Qol Medical, LLC | $34.01 | 2024 | Sucraid |
| Ferring Pharmaceuticals INC. | $27.44 | 2019-2022 | |
| Lilly USA, LLC | $25.17 | 2025 | Omvoh |
| Aimmune Therapeutics, INC. | $21.87 | 2025 | Zenpep |
| Endo Pharmaceuticals INC. | $18.09 | 2019 | |
| Intra-Sana Laboratories | $16.06 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Novo Nordisk INC | $14.69 | 2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $11.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Degayner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.